Apart from LDHA, miR-449a had also been shown to inhibit the growth of endometrial cancer, osteosarcoma, breast cancer, glioma and non-small-cell lung cancer cells by targeting the steroid receptor coactivator [39], Enhancer Of Zeste 2 Polycomb Repressive Complex 2 (EZH2) [40], Pleomorphic adenoma gene like-2 [41], Notch Receptor 1 (Notch1) [42] and High Mobility Group Box 1 (HMGB1) [43], respectively. This evidence concerns the gene HMGB1 and endometrial cancer.